Department of Ophthalmology, Ankara University Faculty of Medicine, Ankara, Turkey.
J Ocul Pharmacol Ther. 2012 Dec;28(6):636-9. doi: 10.1089/jop.2012.0032. Epub 2012 Jun 25.
To evaluate the functional and anatomical outcome after intravitreal ranibizumab injection in 2 patients with cystoid macular edema (CME) related to Irvine-Gass syndrome.
Two patients with pseudophakic CME refractory to current standard topical treatment were enrolled in this study. Intravitreal (0.5 mg/0.05 mL) ranibizumab injection was performed. Baseline visits included best-corrected visual acuity (BCVA), a fundus examination, optical coherence tomography (OCT), and fundus fluorescein angiography (FA). The main outcome measures were changes in visual acuity, retinal thickness on OCT, and complications related to treatment.
FA and OCT confirmed the diagnosis of pseudophakic CME in both cases. The initial BCVA was 5/100 in the first case. After 1 injection of intravitreal ranibizumab, retinal edema totally regressed and BCVA improved to 6/10. The central macular thickness (CMT) measured with OCT was 379 μm at baseline and decreased to 227 μm at the 16-month visit. The initial BCVA was 5/10 in the second case. It improved to 8/10 after 2 ranibizumab injections and remained unchanged at the 21-month visit. The CMT measured with OCT was 419 μm at baseline and decreased to 243 μm at the final follow-up. There were no ocular or systemic complications related to the intravitreal injections.
Intravitreal ranibizumab appeared to be an effective treatment of macular edema related to Irvine-Gass syndrome. Prospective controlled studies are warranted to compare the long-term safety and efficacy between intravitreal ranibizumab and other treatment options in cases of Irvine-Gass syndrome.
评估 2 例与 Irvine-Gass 综合征相关的囊样黄斑水肿（CME）患者玻璃体腔内注射雷珠单抗后的功能和解剖结果。
本研究纳入了 2 例对当前标准局部治疗反应不佳的白内障术后 CME 患者。行玻璃体腔内（0.5mg/0.05ml）雷珠单抗注射。基线访视包括最佳矫正视力（BCVA）、眼底检查、光学相干断层扫描（OCT）和眼底荧光素血管造影（FA）。主要观察指标是视力变化、OCT 视网膜厚度和与治疗相关的并发症。
FA 和 OCT 均证实了 2 例患者的白内障术后 CME 诊断。首例患者的初始 BCVA 为 5/100。玻璃体腔内注射雷珠单抗 1 次后，视网膜水肿完全消退，BCVA 提高至 6/10。OCT 测量的黄斑中心厚度（CMT）在基线时为 379μm，在 16 个月访视时降至 227μm。第 2 例患者的初始 BCVA 为 5/10。玻璃体腔内注射雷珠单抗 2 次后提高至 8/10，21 个月访视时无变化。OCT 测量的 CMT 在基线时为 419μm，在最终随访时降至 243μm。玻璃体腔内注射无相关眼内或全身并发症。
玻璃体腔内注射雷珠单抗似乎是治疗与 Irvine-Gass 综合征相关的黄斑水肿的有效方法。需要前瞻性对照研究来比较玻璃体腔内注射雷珠单抗与 Irvine-Gass 综合征其他治疗选择的长期安全性和疗效。
